Literature DB >> 8934157

Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results.

R E Sampliner1, B Fennerty, H S Garewal.   

Abstract

BACKGROUND: Barrett's esophagus is a premalignant lesion for esophageal adenocarcinoma. This study tests the hypothesis that re-injury of the metaplastic the epithelium in an acid-controlled environment will result in reversal of Barrett's to squamous epithelium.
METHODS: Patients with at least 2 cm of Barrett's esophagus were treated with omeprazole, and half the circumference of the Barrett's was treated with multipolar electrocoagulation (MPEC); the other half served as an internal control. After 6 months, the remaining Barrett's esophagus was treated with MPEC.
RESULTS: Twenty-four hour esophageal pH of less than 4 averaged 1.8% on a mean dose of 56 mg/day of omeprazole. Ten patients had visual and biopsy elimination of the targeted section of Barrett's esophagus after an average of 2.5 MPEC sessions. The remainder of the Barrett's esophagus is being treated in 9 patients; currently 5 have no evidence of Barrett's.
CONCLUSIONS: The combination of control of esophageal acid exposure and reinjury of the metaplastic epithelium reverses Barrett's esophagus to squamous epithelium as determined by endoscopy and biopsy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8934157     DOI: 10.1016/s0016-5107(96)70004-4

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  31 in total

1.  Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus.

Authors:  H Tigges; K H Fuchs; J Maroske; M Fein; S M Freys; J Müller; A Thiede
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

Review 2.  Endoscopic ablation of Barrett's esophagus.

Authors:  M B Fennerty
Journal:  Curr Gastroenterol Rep       Date:  1999-06

Review 3.  Current status of ablative therapies in esophageal disorders.

Authors:  P Sharma
Journal:  Curr Gastroenterol Rep       Date:  2001-06

Review 4.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

Review 5.  How should Barrett's ulceration be treated?

Authors:  J H Peters; K K Wang
Journal:  Surg Endosc       Date:  2004-01-12       Impact factor: 4.584

Review 6.  High grade dysplasia: surveillance, mucosal ablation, or resection?

Authors:  Robert J Korst; Nasser K Altorki
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

Review 7.  Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation.

Authors:  Richard E Sampliner
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

8.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

9.  Barrett's esophagus: endoscopic treatments II.

Authors:  Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

Review 10.  Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma.

Authors:  Cadman L Leggett; Emmanuel C Gorospe; Kenneth K Wang
Journal:  Gastroenterol Clin North Am       Date:  2013-03       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.